Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621924 | 0.87 | ALDH1A1 (0.59) | CYP1A2ALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL24665898 | 0.86 | CYP1A2 (0.61) | CYP1A2TSHRALDH1A1NPC1MEN1 | |
| SCHEMBL27369455 | 0.82 | TSHR (0.57) | CYP1A2TSHRALDH1A1NPC1MEN1 | |
| SCHEMBL10807639 | 0.82 | CYP1A2 (0.61) | CYP1A2TSHRALDH1A1NPC1MEN1 | |
| SCHEMBL6909959 | 0.82 | PGR (0.53) | ALDH1A1GAA | |
| SCHEMBL6363131 | 0.81 | MAPK8 (0.64) | TSHRALDH1A1KMT2ALMNAAGER | |
| SCHEMBL6366020 | 0.81 | PGR (0.64) | TSHRALDH1A1KMT2ALMNAAGER | |
| SCHEMBL6955745 | 0.80 | CYP1A2 (0.59) | CYP1A2TSHRALDH1A1NPC1MEN1 | |
| SCHEMBL11098187 | 0.80 | CYP1A2 (0.59) | CYP1A2TSHRALDH1A1NPC1MEN1 | |
| SCHEMBL16822023 | 0.80 | CYP1A2 (0.59) | CYP1A2TSHRALDH1A1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
| EP-1317013-B1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEM CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8022617-B2 | Organic compound, charge-transporting material, composition for charge-transporting material and organic electroluminescent device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | disclosed |
| US-20090284134-A1 | ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-6942948-B2 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-09-13 | — | — | US | disclosed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20030165733-A1 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | CYP1A2 878/4885TSHR 3766/4885ALDH1A1 2458/4885 |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | CYP1A2 434/4885TSHR 1946/4885ALDH1A1 861/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CYP1A2 4174/4885TSHR 4292/4885ALDH1A1 2972/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | CYP1A2 1215/4885TSHR 2127/4885ALDH1A1 1411/4885 |
| US-20090284134-A1 | ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | SLCO4C1, SLCO2A1, SLCO2B1 | CYP1A2 860/4885TSHR 3808/4885ALDH1A1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.